Telix Pharmaceuticals Stock

Telix Pharmaceuticals Quick Ratio

Delisted·Jun 19, 2026

The Quick Ratio (Acid Test) of Telix Pharmaceuticals (TLX.AX) as of Aug 22, 2026 is 1.27. In the previous year, Quick Ratio (Acid Test) was 2.66 — a change of -52.50% (lower).

Quick Ratio

1.27

YoY

-52.50%

Last updated:

Quick Ratio (Acid Test) of Telix Pharmaceuticals is 2026 1.27 . Quick Ratio (Acid Test) of Telix Pharmaceuticals was 2025 2.66 . It decreases by -52.50% lower compared to the previous year.
Access this data via the Eulerpool API

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Quick Ratio (Acid Test) of Telix Pharmaceuticals is 1.27 in 2026.

Quick Ratio (Acid Test) of Telix Pharmaceuticals changed from 2.66 to 1.27, representing a -52.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals